4//SEC Filing
Blumenkranz Mark S. 4
Accession 0001415889-23-010282
CIK 0001479419other
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 8:00 PM ET
Size
14.7 KB
Accession
0001415889-23-010282
Insider Transaction Report
Form 4
Blumenkranz Mark S.
Director
Transactions
- Award
Common Stock
2023-06-22+1,100→ 11,691 total - Award
Common Stock
2023-06-22+3,784→ 10,591 total - Award
Stock Option (right to buy)
2023-06-22+2,500→ 2,500 totalExercise: $14.56Exp: 2033-06-21→ Common Stock (2,500 underlying) - Award
Stock Option (right to buy)
2023-06-22+5,046→ 5,046 totalExercise: $14.56Exp: 2033-06-21→ Common Stock (5,046 underlying)
Holdings
- 168,454(indirect: See footnote)
Common Stock
- 1,276(indirect: See footnote)
Common Stock
Footnotes (8)
- [F1]Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.
- [F2]Includes 5,424 unvested RSUs.
- [F3]Grant of RSUs under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.
- [F4]Includes 6,524 unvested RSUs.
- [F5]These securities are held directly by Lagunita Biosciences, LLC ("Lagunita"). The reporting person is a managing partner of Lagunita and may be deemed to have beneficial ownership over the Lagunita Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F6]These securities are held directly by Garland Investments, L.P. ("Garland"). The reporting person is a managing partner of Garland and may be deemed to have beneficial ownership over the Garland Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F7]This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.
- [F8]This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.
Documents
Issuer
Kala Pharmaceuticals, Inc.
CIK 0001479419
Entity typeother
Related Parties
1- filerCIK 0001614869
Filing Metadata
- Form type
- 4
- Filed
- Jun 22, 8:00 PM ET
- Accepted
- Jun 23, 8:00 PM ET
- Size
- 14.7 KB